查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1434967

僵直性脊椎炎市場：按藥物、分子類型、作用機制、給藥途徑、劑型和最終用戶分類 - 2024-2030 年全球預測

Ankylosing Spondylitis Market by Drug (Cimzia, Cosentyx, Enbrel), Type of Molecule (Biologics, Small Molecules), Mechanism Of Action, Route Of Administration, Dosage Forms, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年僵直性脊椎炎市場規模為51.8億美元，2024年達56億美元，預計2030年將達90.6億美元，複合年成長率為8.31%。

僵直性脊椎炎的全球市場

主要市場統計
基準年[2023] 51.8億美元
預測年份 [2024] 56億美元
預測年份 [2030] 90.6億美元
複合年成長率（%） 8.31%
僵直性脊椎炎市場-IMG1

FPNV定位矩陣

FPNV 定位矩陣對於評估僵直性脊椎炎市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對僵直性脊椎炎市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-僵直性脊椎炎市場的市場規模和預測是多少？

2-在僵直性脊椎炎市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3-僵直性脊椎炎市場的技術趨勢和法律規範是什麼？

4-僵直性脊椎炎市場主要供應商的市場佔有率是多少？

5-進入僵直性脊椎炎市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 僵直性脊椎炎的發生率增加
      • 提高疾病診斷和治療意識
      • 整形外科醫院和診斷中心數量增加
    • 抑制因素
      • 治療費用高且缺乏熟練的外科醫生和物理治療師
    • 機會
      • 加速脊椎炎治療的研發支出
      • 治療僵直性脊椎炎的生物製藥的出現
    • 任務
      • 對認證核可藥專利到期的擔憂
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章僵直性脊椎炎藥物市場

  • Cimzia
  • 共感學
  • Enbrel
  • Humira
  • Remicade
  • 辛波尼

第7章依分子類型分類的僵直性脊椎炎市場

  • 生技藥品
  • 低分子

第8章僵直性脊椎炎市場的作用機制

  • Cyclooxygenase抑制劑
  • 腫瘤壞死因子抑制劑

第9章僵直性脊椎炎市場：依給藥途徑

  • 口服
  • 胃腸外的

第10章僵直性脊椎炎市場依劑型分類

  • 液體
  • 固體的

第11章僵直性脊椎炎市場：依最終用戶分類

  • 診所
  • 醫院

第12章北美和南美僵直性脊椎炎市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太地區僵直性脊椎炎市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲僵直性脊椎炎市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：按主要企業分類
  • 主要企業競爭情境分析

第16章競爭組合

  • 主要公司簡介
    • Biothera Pharmaceuticals, Inc. by HiberCell, Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb
    • Celltrion Healthcare Co.,Ltd.
    • Eisai Co., Ltd
    • Eli Lilly and Company
    • Hetero Drugs Limited
    • Novartis AG
    • Reliance Life Sciences
    • Samsung Bioepis Co., Ltd.
    • Sandoz International GmbH
    • Sanofi-Aventis Groupe SA
    • Shanghai Pharmaceuticals Holding Co., Ltd.
    • Trinity Biotech PLC
    • Xian Janssen Pharmaceutical Ltd
  • 主要產品系列

第17章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-A339DAEFAAAE

[193 Pages Report] The Ankylosing Spondylitis Market size was estimated at USD 5.18 billion in 2023 and expected to reach USD 5.60 billion in 2024, at a CAGR 8.31% to reach USD 9.06 billion by 2030.

Global Ankylosing Spondylitis Market

KEY MARKET STATISTICS
Base Year [2023] USD 5.18 billion
Estimated Year [2024] USD 5.60 billion
Forecast Year [2030] USD 9.06 billion
CAGR (%) 8.31%
Ankylosing Spondylitis Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Ankylosing Spondylitis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Ankylosing Spondylitis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Ankylosing Spondylitis Market, highlighting leading vendors and their innovative profiles. These include Biothera Pharmaceuticals, Inc. by HiberCell, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Celltrion Healthcare Co.,Ltd., Eisai Co., Ltd, Eli Lilly and Company, Hetero Drugs Limited, Novartis AG, Reliance Life Sciences, Samsung Bioepis Co., Ltd., Sandoz International GmbH, Sanofi-Aventis Groupe S.A., Shanghai Pharmaceuticals Holding Co., Ltd., Trinity Biotech PLC, and Xian Janssen Pharmaceutical Ltd.

Market Segmentation & Coverage

This research report categorizes the Ankylosing Spondylitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Cimzia
    • Cosentyx
    • Enbrel
    • Humira
    • Remicade
    • Simponi
  • Type of Molecule
    • Biologics
    • Small Molecules
  • Mechanism Of Action
    • Cyclooxygenase Inhibitors
    • Tumor Necrosis Factor Inhibitors
  • Route Of Administration
    • Oral
    • Parenteral
  • Dosage Forms
    • Liquid
    • Solid
  • End User
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Ankylosing Spondylitis Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Ankylosing Spondylitis Market?

3. What are the technology trends and regulatory frameworks in the Ankylosing Spondylitis Market?

4. What is the market share of the leading vendors in the Ankylosing Spondylitis Market?

5. Which modes and strategic moves are suitable for entering the Ankylosing Spondylitis Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Ankylosing Spondylitis Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of ankylosing spondylitis
      • 5.1.1.2. Growing awareness about diagnostics and treatments for the disease
      • 5.1.1.3. Rising number of orthopedic hospitals and diagnostic centers
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and dearth of skilled surgeons and physiotherapists
    • 5.1.3. Opportunities
      • 5.1.3.1. Acceleration in research and development expenditure for the treatment of the spondylitis
      • 5.1.3.2. The emergence of biologics for treating ankylosing spondylitis
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns related to patent expiration of already approved drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Ankylosing Spondylitis Market, by Drug

  • 6.1. Introduction
  • 6.2. Cimzia
  • 6.3. Cosentyx
  • 6.4. Enbrel
  • 6.5. Humira
  • 6.6. Remicade
  • 6.7. Simponi

7. Ankylosing Spondylitis Market, by Type of Molecule

  • 7.1. Introduction
  • 7.2. Biologics
  • 7.3. Small Molecules

8. Ankylosing Spondylitis Market, by Mechanism Of Action

  • 8.1. Introduction
  • 8.2. Cyclooxygenase Inhibitors
  • 8.3. Tumor Necrosis Factor Inhibitors

9. Ankylosing Spondylitis Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral

10. Ankylosing Spondylitis Market, by Dosage Forms

  • 10.1. Introduction
  • 10.2. Liquid
  • 10.3. Solid

11. Ankylosing Spondylitis Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Hospitals

12. Americas Ankylosing Spondylitis Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Ankylosing Spondylitis Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Ankylosing Spondylitis Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. FPNV Positioning Matrix
  • 15.2. Market Share Analysis, By Key Player
  • 15.3. Competitive Scenario Analysis, By Key Player

16. Competitive Portfolio

  • 16.1. Key Company Profiles
    • 16.1.1. Biothera Pharmaceuticals, Inc. by HiberCell, Inc.
    • 16.1.2. Boehringer Ingelheim International GmbH
    • 16.1.3. Bristol-Myers Squibb
    • 16.1.4. Celltrion Healthcare Co.,Ltd.
    • 16.1.5. Eisai Co., Ltd
    • 16.1.6. Eli Lilly and Company
    • 16.1.7. Hetero Drugs Limited
    • 16.1.8. Novartis AG
    • 16.1.9. Reliance Life Sciences
    • 16.1.10. Samsung Bioepis Co., Ltd.
    • 16.1.11. Sandoz International GmbH
    • 16.1.12. Sanofi-Aventis Groupe S.A.
    • 16.1.13. Shanghai Pharmaceuticals Holding Co., Ltd.
    • 16.1.14. Trinity Biotech PLC
    • 16.1.15. Xian Janssen Pharmaceutical Ltd
  • 16.2. Key Product Portfolio

17. Appendix

  • 17.1. Discussion Guide
  • 17.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANKYLOSING SPONDYLITIS MARKET RESEARCH PROCESS
  • FIGURE 2. ANKYLOSING SPONDYLITIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANKYLOSING SPONDYLITIS MARKET DYNAMICS
  • FIGURE 7. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 8. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2030 (%)
  • FIGURE 10. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 12. ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 14. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2030 (%)
  • FIGURE 16. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 18. ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 22. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 27. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 28. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANKYLOSING SPONDYLITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 6. ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 13. ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 16. ANKYLOSING SPONDYLITIS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 22. ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 151. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 259. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 278. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 279. ANKYLOSING SPONDYLITIS MARKET LICENSE & PRICING